about
Adjuvant bisphosphonates in patients with breast cancer: does the potency matter?Low-intensity continuous ultrasound triggers effective bisphosphonate anticancer activity in breast cancer.Cancer Cell Colonisation in the Bone MicroenvironmentBone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myelomaTumour-derived miRNAs and bone metastasisA transcriptome-proteome integrated network identifies endoplasmic reticulum thiol oxidoreductase (ERp57) as a hub that mediates bone metastasisCancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclastsLysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity.Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers.How do bisphosphonates inhibit bone metastasis in vivo?Cathepsin K inhibitors as treatment of bone metastasis.Development of a new ELISA for serum periostin: evaluation of growth-related changes and bisphosphonate treatment in mice.Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases.TRPV6 calcium channel translocates to the plasma membrane via Orai1-mediated mechanism and controls cancer cell survivalMutational profiling of bone metastases from lung adenocarcinoma: results of a prospective study (POUMOS-TEC)Interaction of platelet-derived autotaxin with tumor integrin αVβ3 controls metastasis of breast cancer cells to bone.Metastasis and bone loss: advancing treatment and prevention.A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancerBisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity.Anti-tumour activity of zoledronic acid.The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer.RANK/RANKL pathway in cancer: Biological activity beyond bone?Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis.International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients.Advances in optical imaging and novel model systems for cancer metastasis research.Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities.Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer.Estrogen related receptor alpha in castration-resistant prostate cancer cells promotes tumor progression in boneBisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class.Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature.Effects of bone-targeted agents on cancer progression and mortality.Emerging therapies in bone metastasis.Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.Lysyl Oxidase Is a Strong Determinant of Tumor Cell Colonization in Bone.Upregulation of the mevalonate pathway by cholesterol depletion abolishes tolerance to N-bisphosphonate induced Vγ9Vδ2 T cell cytotoxicity in PC-3 prostate cancer cells.The role of osteoclasts in breast cancer bone metastasis.TWIST1 expression in breast cancer cells facilitates bone metastasis formation.[Oligometastatic bone disease. Can limited metastatic bone disease be cured? Is there room for local ablative treatments?].In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement.Peroxiredoxin 2 specifically regulates the oxidative and metabolic stress response of human metastatic breast cancer cells in lungs.
P50
Q26781435-D7ECAFCC-D179-4F80-A20C-3124746B60C5Q27306861-44B7460A-A649-489F-A6D4-1489ADC1B199Q28072561-CA727E28-50CE-445C-94CC-DB6AE1A31D32Q28081996-EB27E46F-C7F7-49B7-B40C-8B4F98A508EEQ28086895-7272402B-B730-4BA0-A7C1-C07656D58E99Q28289791-600A4817-7129-4EE1-B307-B46696195467Q30436718-046FE7C0-6AA5-42AD-83E7-ACA35CF6F881Q30573574-B01C0140-FEBC-4A15-AE05-647E179DDC59Q33610285-3A4C6FBA-4108-4E21-9136-7B1C56BF4C41Q34009853-744992D4-8A59-4700-9B60-02D599A4268AQ34013240-090F222C-075E-4456-BBEB-7BA8BDC375B9Q34122023-6E995E17-8660-407C-8809-6F37E0D0D36AQ34131624-6D16F6AA-E38A-43DB-9860-C077DB799B94Q34218298-10C2B12A-EDFB-4855-8869-3052432705DAQ34271752-501DA5A9-04FB-43B8-A7D9-8F4BCD65A7CCQ34508348-8BB4E7C2-B139-457B-8E3F-B3CEB0346C0BQ34617837-E5CC552E-818A-4283-B1C3-BC0BD44692E5Q34999463-A55D7A5D-D8D2-4DED-B62A-30E30FA1164BQ36164448-31831E29-47EC-4280-BBF9-A25010AF4475Q36286655-2817B61F-2F4D-4797-9261-27D4CB30411BQ36299766-6B5E215C-CB39-4EE9-950A-AC298C46F475Q36491425-440AD27A-D29A-415C-B363-825D25FDB3EFQ36645398-0AF42F91-1534-4216-A8F0-7809EDACEBF2Q36720231-B4939D1B-AF35-4DC7-AC1E-5091B3522E48Q36986618-01A8D920-0EF0-45EA-9A30-6FD7402C9D04Q37043903-F6FFFC74-63F8-483F-971B-41703AA34470Q37700375-5C750A8B-945B-4350-9DCC-088A8AFDEF99Q37718338-0D21A22F-F2E9-4692-AF10-9574D9CDD247Q37775202-1D644CF7-5AC8-43E8-A565-19701C230FC1Q37943621-6D65C07B-8D9F-4737-87CF-617899C28647Q38023206-35F6916D-B556-4E8A-92E4-E35573045B2FQ38455451-0A928F1E-57BB-4816-8F54-06B0AAE404E6Q38673148-1C0628D8-1592-40C7-A5EE-1FB90BBD4D8FQ38741210-44C2FD63-5EB9-4437-B509-8F4EA93BEA3BQ38936031-9F7E66F7-67F7-489F-9217-D3C29B31177BQ38985668-CE77E274-36CB-410A-A177-F6311A0BE790Q39016352-CA6BFDBE-F4AB-45A3-BEFE-6972691F605FQ39242994-364C2CC3-87E4-4FA7-A97E-87A63C66F49FQ39266693-A0ED6EE0-EB7D-46AF-AA3E-DCF7EF9BDAA3Q39376892-31EC50E6-AE1A-432F-96A0-49374417A72E
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Philippe Clézardin
@ast
Philippe Clézardin
@en
Philippe Clézardin
@es
Philippe Clézardin
@nl
type
label
Philippe Clézardin
@ast
Philippe Clézardin
@en
Philippe Clézardin
@es
Philippe Clézardin
@nl
prefLabel
Philippe Clézardin
@ast
Philippe Clézardin
@en
Philippe Clézardin
@es
Philippe Clézardin
@nl
P106
P31
P496
0000-0003-0149-4463